Drugs & Targets FDA approves penpulimab-kcqx for non-keratinizing nasopharyngeal carcinoma April 25, 2025Vol.51 No.16
Drugs & Targets FDA grants Breakthrough Therapy designation for B7-H3 CAR T-cell therapy for diffuse intrinsic pontine glioma April 25, 2025Vol.51 No.16
Regulatory News RFK Jr. urges FDA staff to resist “agency capture” by special interests and resist “deep state”Whistleblowers will be “honored” April 18, 2025Vol.51 No.15By Jacquelyn Cobb
Drugs & Targets FDA approves nivolumab + ipilimumab for unresectable or metastatic HCC April 18, 2025Vol.51 No.15
Drugs & Targets FDA to phase out animal testing requirement for monoclonal antibodies, other drugs April 18, 2025Vol.51 No.15
Cancer Policy Federal judge nixes FDA’s LDT rule, says agency exceeded its authority April 11, 2025Vol.51 No.14
Drugs & Targets FDA approves Vitrakvi for NTRK gene fusion-positive solid tumors April 11, 2025Vol.51 No.14
FreeIn the Archives In an oral history now taken down by FDA, Andrew von Eschenbach recounts his stint as the head of both FDA and NCI—simultaneously April 04, 2025Vol.51 No.13By Jacquelyn Cobb
Drugs & Targets FDA approves durvalumab for muscle invasive bladder cancer April 04, 2025Vol.51 No.13
